Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Slideshows|September 20, 2019
At a Glance: Asthma Biologics
Author(s)Rachael Zimlich, RN, BSN
Advertisement
As featured in Asthma Care Complications from our September issue. Swipe through the images for product descriptions and links to prescribing information.Â
Advertisement
Related to this article
The expert explains 2025-1016 flu, COVID-19, and RSV vaccine updates from AAP, ACOG, AAFP, and IDSA, and what changing schedules mean for pharmacists.
Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
5